Author： Markoff Brian MacMillan John Kumra Vivek
Publisher： Humana Press, Inc
ISSN： 1080-0549
Source： Clinical Reviews in Allergy and Immunology, Vol.20, Iss.3, 2001-06, pp. : 341-355
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Asthma continues to be a challenging disease to treat in both the inpatient and outpatient settings. The growing database on therapeutic interventions at the time of transition from the acute to chronic phase of this disease is encouraging. Glucocorticoids and inhaled -agonists clearly reduce readmission and relapse. Other medications and educational interventions also appear effective. Still, no true discharge guidelines have been established. Multiple statements by consensus panels have recommended using FEV1 or PEFR as indicators of readiness for discharge, but this has not been prospectively validated from either the emergency department or inpatient setting. In contrast, some studies argue that pulmonary functions do not accurately predict relapse and readmission, so the usefulness of these discharge recommendations is debatable. Large studies, especially in the adult asthmatic population, are needed to validate these recommendation.
Related content
Allergy and Asthma Proceedings, Vol. 25, Iss. 6, 2004-11 ,pp. :
Access to resources
Recommend
Mechanisms of Inflammation in the Asthmatic Patient
Allergy and Asthma Proceedings, Vol. 14, Iss. 1, 1993-01 ,pp. :
Treatment of the Unusually Difficult Asthmatic Patient
Allergy and Asthma Proceedings, Vol. 18, Iss. 3, 1997-05 ,pp. :
Anaphylactic Deaths in Asthmatic Patients
Allergy and Asthma Proceedings, Vol. 10, Iss. 4, 1989-07 ,pp. :
Summary of Symposium on Asthmatic Deaths
Allergy and Asthma Proceedings, Vol. 7, Iss. 5, 1986-09 ,pp. :